(Q36478796)

14 August 2017

1 reference

title

Airway selectivity: an update of pharmacokinetic factors affecting local and systemic disposition of inhaled steroids (English)

1 reference

14 August 2017

1 reference

Staffan Edsbäcker

1

1 reference

14 August 2017

Carl-Johan Johansson

series ordinal

2

1 reference

14 August 2017

publication date

1 June 2006

1 reference

Basic and Clinical Pharmacology and Toxicology

14 August 2017

published in

1 reference

14 August 2017

volume

98

1 reference

14 August 2017

issue

6

1 reference

14 August 2017

page(s)

523-536

1 reference

Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Lung deposition and systemic availability of fluticasone Diskus and budesonide Turbuhaler in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Effect of long-term treatment with inhaled budesonide on adult height in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Expression and localization of CYP3A4 and CYP3A5 in human lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Anti-inflammatory actions of steroids: molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Efficacy and safety of inhaled corticosteroids. New developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

New Glucocorticosteroids with an improved therapeutic ratio?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Beclomethasone dipropionate: absolute bioavailability, pharmacokinetics and metabolism following intravenous, oral, intranasal and inhaled administration in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Adrenal suppression with dry powder formulations of fluticasone propionate and mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler and budesonide from Turbuhaler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Effects of carbon monoxide inhalation during experimental endotoxemia in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Steroidal fatty acid esters

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Dose response and therapeutic index of inhaled corticosteroids in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Dose-proportional pharmacokinetics of budesonide inhaled via Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Effects of hydrofluoroalkane formulations of ciclesonide 400 microg once daily vs fluticasone 250 microg twice daily on methacholine hyper-responsiveness in mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Safety of inhaled and intranasal corticosteroids: lessons for the new millennium

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Pharmacokinetics of epimeric budesonide and fluticasone propionate after repeat dose inhalation--intersubject variability in systemic absorption from the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Nasal retention of budesonide and fluticasone in man: formation of airway mucosal budesonide-esters in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Treatment of exercise-induced asthma with beclomethasone dipropionate in children with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Inhaled fluticasone propionate by diskus in the treatment of asthma: a comparison of the efficacy of the same nominal dose given either once or twice a day.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Human receptor kinetics, tissue binding affinity, and stability of mometasone furoate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Pharmacologic importance of the reversible fatty acid conjugation of budesonide studied in a rat cell line In vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Pharmacological factors that influence the choice of inhaled corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

Rationale for once-daily therapy in asthma: compliance issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1742-7843.2006.PTO_355.X

10.1111/J.1742-7843.2006.PTO_355.X

21 January 2018

Identifiers

DOI

1 reference

14 August 2017

1 reference